Table 3

Serious adverse events in study cohorts according to treatment in Apulia and Lombardy regions from 2010 to 2018

Serious adverse eventsApuliaLombardy
SGLT-2i
(531)
GLP-1RA
(459)
Insulin
(7027)
Other AHAs
(5704)
SGLT-2i
(786)
GLP-1RA
(759)
Insulin
(10 950)
Other AHAs
(8160)
n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)
Hypoglycemia0 (0.0)0 (0.0)27 (0.4)18 (0.3)0 (0.0)2 (0.3)42 (0.4)42 (0.5)
Ketoacidosis0 (0.0)1 (0.2)7 (0.1)7 (0.1)1 (0.1)1 (0.1)7 (0.1)4 (0.1)
Diabetic coma0 (0.0)0 (0.0)9 (0.1)8 (0.1)0 (0.0)0 (0.0)22 (0.2)12 (0.2)
Syncope1 (0.2)4 (0.9)79 (1.1)95 (1.7)3 (0.4)6 (0.8)142 (1.3)117 (1.4)
Lower limb amputations6 (1.1)2 (0.4)109 (1.6)84 (1.5)7 (0.9)11 (1.5)323 (3.0)161 (2.0)
Fractures5 (0.9)9 (2.0)385 (5.5)392 (6.9)11 (1.4)28 (3.7)575 (5.3)535 (6.6)
  • AHA, antihyperglycemic agent; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose cotransporter-2 inhibitor.